EUVIMEDEUVIMED entdecken
Crossref

Tailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach

Alice Nervo, Matteo Ferrari, Elisa Vaccaro, Enrica Migliore, Giovanni Gruosso, Anna Roux, Alessandro Piovesan, Emanuela Arvat

Endocrine · 02.10.2024 · 87 (2) · 724-733

DOI: 10.1007/s12020-024-04061-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine, online erschienen am 02.10.2024. Verfasst von Alice Nervo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy. alice…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Quinolines, Piperidines, Quinazolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In differentiated/poorly differentiated (DTC/PDTC) or medullary thyroid cancer (MTC) treated with kinase inhibitors (KIs), additional treatments (ATs) can be performed in selected cases. METHODS: We retrospectively analysed all the ATs performed in our center in KI-treated TC patients, evaluating the subsequent KI modulation, the local PD in case of loco-regional procedure (LRP) and the AT-related complications. DTC/PDTC patients with or without progressive disease before the first AT (PD and NO PD GROUP, respectively) were analysed separately. RESULTS: In our center, 32 ATs (30 LRPs and 2 radioactive iodine treatments) were performed in 14 DTC/PDTC patients and 4 MTC subjects after the start of systemic therapy with lenvatinib or vandetanib (27 and 5 ATs, respectively). Brain was the most treated site (11/30 LRPs) and external beam radiation was the most employed LRP (18/30 LRPs). KIs dose reduction or discontinuation of KI therapy (at least transient) was performed after 50% of ATs in DTC/PDTC NO PD GROUP. The KI was maintained at the same dosage after 75% and 50% of the ATs performed in DTC/PDTC PD GROUP and MTC, respectively. During the follow-up, local PD was detected after 14 LRPs. Local progression-free survival (LPFS) was significantly shorter in DTC/PDTC PD GROUP in comparison to NO PD GROUP (12 month-LPFS 91.7% versus 15.2%); in patients with MTC, 12 month-LPFS was 50%. AT-related AEs were mostly G1-G2. CONCLUSIONS: In selected DTC/PDTC without previous PD and treated with a multimodal strategy, local disease control is generally maintained regardless the KI dose modulation. In DTC/PDTC patients with previous limited PD and in MTC subjects, the choice of performing a LRP and continue the ongoing KI therapy must consider the risk of early local progression. AT-related AEs in KI treated patients were mild in most cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsQuinolinesPiperidinesQuinazolinesPhenylurea CompoundsCarcinoma, NeuroendocrineProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultCombined Modality TherapyIodine Radioisotopes

Stichwörter der Autor:innen

Kinase inhibitorLoco-regional treatmentPersonalized therapyTumour board

Substanzen

lenvatinibvandetanibQuinolinesPiperidinesQuinazolinesPhenylurea CompoundsProtein Kinase InhibitorsAntineoplastic AgentsIodine Radioisotopes

Autor:innen und Institutionen

  • Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy. alice.nervo@gmail.com.
  • Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.
  • Cancer Epidemiology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Zitieren

APA

Nervo, A., Ferrari, M., Vaccaro, E., Migliore, E., Gruosso, G., Roux, A., Piovesan, A., & Arvat, E. (2024). Tailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach. Endocrine, 87(2), 724-733. https://doi.org/10.1007/s12020-024-04061-2

Vancouver

Nervo A, Ferrari M, Vaccaro E, Migliore E, Gruosso G, Roux A, et al. Tailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach. Endocrine. 2024;87(2):724-733. doi:10.1007/s12020-024-04061-2

BibTeX
@article{Nervo2024,
  author = {Nervo, Alice and Ferrari, Matteo and Vaccaro, Elisa and Migliore, Enrica and Gruosso, Giovanni and Roux, Anna and Piovesan, Alessandro and Arvat, Emanuela},
  title = {Tailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach},
  journal = {Endocrine},
  year = {2024},
  volume = {87},
  number = {2},
  pages = {724--733},
  doi = {10.1007/s12020-024-04061-2}
}
Kostenlos starten →